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Abstract Through the course of over three decades, non-
human primate (NHP) studies on cell-based therapies
(CBTs) for Parkinson’s disease (PD) have provided insight
into the feasibility, safety and efficacy of the approach,
methods of cell collection and preparation, cell viability, as
well as potential brain targets. Today, NHP research con-
tinues to be a vital source of information for improving cell
grafts and analyzing how the host affects graft survival,
integration and function. Overall, this article aims to dis-
cuss the role that NHP models of PD have played in CBT
development and highlights specific issues that need to be
considered to maximize the value of NHP studies for the
successful clinical translation of CBTs.
Keywords Parkinson’s disease  Nonhuman primates 
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Introduction
Since the early 1980s, scientists have relied on nonhuman
primate (NHP) models to assess whether cell-based thera-
pies (CBTs) can be beneficial for Parkinson’s disease (PD).
CBT strategies and NHP models of PD emerged into the
scientific arena simultaneously. In a way, the availability of
the new NHP models fueled CBT progression towards
clinical application.
As the main aim of CBTs for PD was and still is the
replacement of neurons lost in the disease, PD animal models
with neurotoxin-induced neuronal loss became an ideal plat-
form to assess the approach. CBT studies in rodent models
provided invaluable information on neuronal survival,
migration and integration after grafting (Kim et al. 2013).
Clinical translation of CBTs requires progressive evaluation
in different species and as a first-in-class and invasive brain
therapy, NHP experiments are a logical next step (Capitanio
and Emborg 2008). Compared to rodents that are inbred,
NHPs are outbred. Behavioral outcome measures such as fine
motor skills, which are affected in PD, can be easily tested in
NHPs but not in other large species, like pigs. Clinically rel-
evant behavioral outcome measures are critical to determine
the efficacy of the strategy, including the selection of intrac-
erebral grafting targets. In that regard, NHPs and humans
share a similar organization of the striatum, with the caudate
nucleus and the putamen clearly delineated by the white
matter tracts of the internal capsule. In rodents, transecting
white matter tracts perforate throughout the striata, without
presenting a physical barrier for cell distribution (Fig. 1).
In this article, we aim to discuss the role of NHP models of
PD in CBT development, keeping in perspective how the field
of PD is evolving, analyze ongoing advances in CBTs and the
issues that need to be considered to maximize the value of NHP
studies for the successful clinical translation of CBTs for PD.
Parkinson’s disease: then and now
Parkinson’s disease (PD) is the 2nd most common neu-
rodegenerative disorder affecting around 1% of the popu-
lation over the age of 60 (Driver et al. 2009). When CBTs
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were first envisioned for actual clinical application, the
conceptualization of PD suggested that it was an ideal
candidate disease for brain repair. Patients were diagnosed
by typical motor symptoms (resting tremor, rigidity,
bradykinesia, and postural instability), which were associ-
ated with the loss of dopaminergic (DAergic) nigral neu-
rons. As the symptoms responded to oral dopamine (DA)
replacement therapy, it was expected that dopamine
replacement with a cell source should be an efficient way to
securely and locally deliver DA and, basically, cure PD. In
addition, the brain was viewed as an immunoprivileged,
postmitotic organ.
The understanding of PD and the brain has evolved over
time, which affects the application of CBT strategies.
Today, PD diagnoses still depend on the presence of typical
motor symptoms, and postmortem confirmation of nigral
DAergic neuron loss and the presence of intracytoplasmic
neuronal inclusions termed Lewy bodies [LBs; (Vermilyea
and Emborg 2015)]. Yet, PD is now recognized as a
complex neurodegenerative disorder that includes non-
motor symptoms (NMS). Depression, anxiety, loss of sense
of smell, gastrointestinal dysfunction and cardiac dysau-
tonomia are common PD NMS, which are associated with
neurodegeneration in other areas of the central and
peripheral nervous system (Chaudhuri and Odin 2010;
Chaudhuri et al. 2011). Interestingly, NMS precede the
onset of the movement disorder by decades and are now
proposed as prodromal signs of the disease (Postuma et al.
2012). Earlier PD diagnoses would increase the chances of
success of neuroprotective strategies. In that regard, brain
immunoreactivity has been documented (Kordower et al.
1997; Roitberg et al. 2004; Tambur 2004) and neuro-in-
flammation has been linked to PD neurodegeneration,
suggesting that immunomodulation can be neuroprotective
(Kannarkat et al. 2013). Neurogenesis has been docu-
mented in the adult brain of rodents (Altman and Das 1965;
Kaplan and Hinds 1977; Kempermann et al. 1997), NHPs
(Gould et al. 1999) and humans (Eriksson et al. 1998), and
directed neurogenesis has been discussed for self-brain
repair (Rakic 2004).
Another chain of events that led to findings with great
implications for PD and CBTs started in 1996, when
mutations in the alpha-synuclein (a-syn) gene were found
in familial forms of PD (Polymeropoulos et al. 1997).
Subsequent studies identified a-syn as the main component
of LBs (Spillantini et al. 1997, 1998). Then, in 2008 LBs
were reported in dopaminergic fetal grafts of PD patients
that were transplanted a decade earlier, suggesting that the
grafts ‘‘caught PD’’ from the host (Li et al. 2008; Kordower
et al. 2008). Since then, a-syn research has taken a center
stage in PD research (Bendor et al. 2013; Vermilyea and
Emborg 2015). Investigations on whether a-syn has prion-
like activity revitalized the Braak and Braak hypothesis
that PD may start in the brainstem and propagate through
the neural axis (Braak et al. 2004; Chu and Kordower 2015;
Hilker et al. 2011). Studies on protein aggregation followed
(Luk et al. 2009), as well as the search for neuroprotective
approaches aiming to prevent aggregation (Kalia et al.
2015). It should be noted that the cause of PD is still
unclear and that the question of whether the early periph-
eral symptoms reflect where PD starts or less neuroplas-
ticity is being debated (Engelender and Isacson 2016).
NHP models of PD used for CBT evaluation
Common marmoset, vervet and macaque monkeys are the
most used NHP species for CBT studies. To the best of our
knowledge, only neurotoxin-induced NHP models of PD
have been used as testing platforms for CBTs, mainly by
the administration of 6-hydroxydopamine (6-OHDA) or
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
although new models are emerging (Table 1).
6-OHDA (Senoh and Witkop 1959) is preferentially
used in common marmoset monkeys (Ungerstedt 1968;
Blandini et al. 2008; Eslamboli et al. 2005). As 6-OHDA
does not cross the blood–brain barrier (BBB), it is stereo-
taxically injected directly into the right or left striatum,
medial forebrain bundle or substantia nigra, inducing uni-
lateral motor impairments. The neurotoxin is selectively
taken up by catecholaminergic neurons through mono-
amine transporters, and induces sympathetic neuronal loss
by increasing the production of reactive oxygen species
Fig. 1 Coronal brain sections of A rhesus and a mouse brain
immunostained against tyrosine hydroxylase (TH) highlighting the
comparison of brain size and complexity. Scale bar 1 cm. Cd caudate,
ic internal capsule, Put putamen, ac anterior commissure, CPu
caudate and putamen
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(ROS), and disrupting energy metabolism and neuronal
activity (Blum et al. 2001).
MPTP (Davis et al. 1979; Langston et al. 1983) is most
commonly administered to macaque monkeys, although it
is also used in other old and new world NHP species (Fox
and Brotchie 2010; Emborg 2007). Unlike 6-OHDA,
MPTP crosses the BBB and is administered to NHPs via
s.c., i.m., i.v. or intracarotid artery (ICA) injection. Severity
of PD symptoms depends on route, dose and frequency of
administration; dosing regimen varies between species
(Emborg 2007). In the brain, MPTP is transformed into its
toxic metabolite MPP? by monoamine oxidase-B (MAO-
B). MPP? is then selectively taken up by the DA trans-
porter into dopaminergic neurons where it disrupts normal
mitochondrial respiration by acting as a mitochondrial
complex I inhibitor, leading to oxidative stress and apop-
tosis (Przedborski and Vila 2001).
Although it can be argued that neurotoxic models are
missing critical components of PD, such as ‘‘true’’ LB
formation (Dauer and Przedborski 2003), several reasons
justify their use to test CBTs as DA replacement/network
restoration strategies: (1) neurotoxin-induced models pre-
sent PD-like motor symptoms and dopaminergic nigros-
triatal loss, (2) they are well characterized, and (3) they can
be induced in a protracted period of time, which facilitates
their use as testing platforms.
We agree with the concept that an ideal NHP model of
PD should mimic the disease by replicating its etiology,
which should induce the pathological mechanisms that give
rise to the typical symptoms. Yet, although great progress
has been made towards understanding the complexity of
PD and possible pathways of neurodegeneration, its cause
is still unknown. Neurotoxin-based models attempt to
capitalize on the knowledge that exposure to environmental
toxins is a PD risk factor. In that regard, both neurotoxins
trigger mechanisms associated with neurodegeneration in
PD. In addition to disrupting energy metabolism and
increasing oxidative stress, dosing with 6-OHDA and
MPTP induces inflammatory responses (Rodriguez-Pal-
lares et al. 2007; Joglar et al. 2009; McGeer et al. 2003).
MPTP dosing has also been shown to trigger an increase in
a-syn expression and, in some cases, its accumulation
Table 1 Comparison between NHP models of PD highlighting key features for evaluation of CBTs for DA cell replacement








6-OHDA Yes Yes No Not reported Unilateral model. Requires multiple intracerebral
stereotaxic injections to induce a stable lesion
MPTP systemic Yes Yes Yes Upregulation of
a-syn
Bilateral model. Needs to be individually titrated, and
depending on dosing paradigm may require from one




Yes Yes Yes Upregulation of
a-syn, possible
aggregates
Same as MPTP systemic plus animals may require more
intensive care post intoxication
MPTP ICA Yes Yes No Not reported Unilateral model. Requires surgical set up; Induces a
stable and reproducible lesion
MPTP
ICA?aging
Yes Yes No Not reported Same as MPTP ICA except MPTP dose needs to be 2/3
of younger animals. Monkeys may require more
intensive care post intoxication
Aged NHPs Yes Yes No Translocation of
a-syn














No Yes Unknown Overexpression
of a-syn,
aggregates






Unknown Unknown Unknown Bilateral model
6-OHDA 6 hydroxydopamine, a-syn alpha-synuclein, MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, ICA intracarotid artery, L-DOPA
L-3,4-dihydroxyphenylalanine, LIDs L-DOPA induced dyskinesias
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(Halliday et al. 2009; Kowall et al. 2000; McCormack et al.
2008).
Other identified PD risk factors include aging and
genetic mutations which are exploited for modeling pur-
poses (Emborg 2007). Studies in aged NHPs with or
without MPTP have been reported. Intact aged animals
present subtle PD-like symptoms (e.g.: slowness and
overall decreased amount of movement) and nigrostriatal
dopaminergic loss, with individual variations. As the
symptoms in aged monkeys do not respond to DA
replacement therapies, the animals are not useful models to
assess cell replacement strategies. In contrast, aged animals
intoxicated with MPTP present the typical motor and
pathological syndrome observed after neurotoxin, plus the
background aged condition associated with PD, and could
be useful testing platforms, yet CBT studies in models
combining aging and neurotoxins have not been reported.
Genetic-like NHP PD models have been induced by
intracerebral injection of viral vectors encoding for mutateda-
syn or administration of LB extracts [see review (Vermilyea
and Emborg 2015)]. Adeno-associated viral (AAV) vector-
induced nigral overexpression of human a-syn wild type and
A53T has been shown to induce PD-like motor symptoms,
significant nigral dopaminergic cell loss, anda-syn aggregates
in common marmoset monkeys (Eslamboli et al. 2007; Kirik
et al. 2003). AAV and lentiviral vectors encoding for A53T a-
syn have also been used in cynomolgus (Koprich et al. 2016)
and rhesus (Yang et al. 2015) monkeys. In both studies, A53T
a-syn induced nigral cell loss and a-syn accumulation and
aggregation; behavioral changes were not reported. A com-
bination of AAV-induced overexpression of Parkin and A53T
a-syn was reported in cynomolgus; although the animals had
decreased striatal dopaminergic markers and a-syn accumu-
lation and phosphorylation, no motor symptoms were
observed. It should be noted that in vervet monkeys nigral
injection of AAV expressing a short hairpin RNA (shRNA) to
knock down a-syn induced a region-specific decrease in TH-
positive nigral cell number and striatal innervation compared
to animals that received scrambled shRNA; no behavioral
changes were reported (Collier et al. 2016). Intracerebral
inoculation of a-syn fibrils has been extensively used in
rodents, but not yet in monkeys (e.g.: (Luk et al. 2012; Pau-
mier et al. 2015)). Instead cadaveric LB extracts have been
injected into the striatum or nigra of cynomolgus monkeys
with or without previous MPTP, (Recasens et al. 2014). The
extracts induced some decreases in striatal and nigral
dopaminergic markers and increases in a-syn expression, yet
PD motor symptoms were not detected. It should be noted that
with exception of the AAV a-syn studies in marmosets, all the
other reports in genetic-like models were performed in a few
subjects; further characterization and validation of the models
are needed before they are used as testing platforms for CBTs.
Transgenic NHP models induced by oocyte injection of
lentiviral vectors encoding for mutations of interest are
emerging; transgenic rhesus monkeys overexpressing mutant
A53T a-syn have been reported (Niu et al. 2015). The authors
also reported some behavioral deficits after 1.5–2.5 years of
age. New technologies such as CRISPR/Cas9 genomic editing
present an opportunity to create NHP models with PD asso-
ciated mutations expressed at physiological levels that may
help clarify the disease onset process, including motor and
non-motor symptoms (Gaj et al. 2016). Timely evaluation of
CBTs in these novel NHP models may provide clues to
understand a-syn-related problems during clinical translation
and define the role of CBTs in global therapies.
CBTs for DA cell replacement: from rodents
and monkeys to PD patients
Fetal mesencephalon and autologous adrenal medullary
tissues were the first sources used to demonstrate the fea-
sibility for DA cell replacement. In 1979, Bjorklund and
Stenevi (Bjorklund and Stenevi 1979) reported positive
effects of fetal grafts in circling behavior of 6-OHDA-
treated rats, and in 1981, Freed et al. (Freed et al. 1981)
showed adrenal graft survival in a similar model. In 1984,
Morihisa and colleagues (Morihisa et al. 1984) transplanted
adrenal medullary tissue and fetal mesencephalic cells into
MPTP-treated parkinsonian rhesus monkeys and showed
some survival of adrenal, but not fetal, cells. In follow-up
experiments, poor survival of transplanted adrenal tissue
was reported (Morihisa et al. 1987) yet as the PD signs
ameliorated, researchers hypothesized that the intense host-
derived dopaminergic sprouting in the transplanted area
was responsible for the behavioral improvements.
Improved graft survival was observed when methods were
applied to minimize the endothelial components (Schueler
et al. 1993). With regard to fetal mesencephalic grafts,
between 1986 and 1994, 15 NHP reports were published
(Bakay et al. 1987; Collier et al. 1987; Redmond et al.
1986, 1988; Sladek et al. 1986; Annett et al. 1990, 1994;
Bankiewicz et al. 1990; Collier et al. 1994; Dubach et al.
1988; Elsworth et al. 1994; Fine et al. 1988; Sladek et al.
1993; Taylor et al. 1990, 1991) demonstrating the feasi-
bility of the approach, as well as different degrees of
antiparkinsonian effects. It should be noted that these
studies were performed in a limited number of NHPs per
treatment group, in most cases the area of the brain targeted
was the caudate nucleus, the animals did not receive
immunosuppression and the effect of antiparkinsonian
medication was not evaluated (Fitzpatrick et al. 2009).
Both CBT approaches were rapidly translated to
humans. In 1985, Backlund et al. reported two cases of
patients receiving adrenal medulla grafts resulting in mild
effects, and in 1987, Madrazo and colleagues showed the
S. C. Vermilyea, M. E. Emborg
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first dramatic improvement of PD symptoms in two
patients (Madrazo et al. 1987). Following these promising
results, several similar case studies were undertaken, with
different, less favorable outcomes [see review: (Redmond
2002)]. Goetz et al. reported the results of a multi-center
study of 19 patients in 1989 (Goetz et al. 1989). The
grafted patients showed minimal temporary antiparkinso-
nian effects, described as decreased mean severity of ‘‘off’’
time (time when the positive effects of pharmacological
treatment wear off) as assessed by both the Activities of
Daily Living subscale of the Unified Parkinson’s Disease
Rating Scale (UPDRS) and the Schwab and England scale.
Yet, the patients’ antiparkinsonian medications could not
be decreased and postoperative morbidity was consider-
able, due to the double surgery (abdominal and brain)
required to harvest the adrenal medulla and then transplant
the cells. Postmortem results revealed poor cell survival
and localized host regional neuronal sprouting, similar to
the results in the NHP experiments.
With regard to fetal mesencephalon grafting, after
multiple case reports in PD patients [see (Freed et al. 1992;
Redmond et al. 1993)] the National Institute of Health
(NIH) funded two prospective, double blind, randomized
control trials aiming to assess the efficacy and safety of
transplanting fetal mesencephalic tissue to treat PD. The
Freed et al. (Freed et al. 2001) trial consisted of 40 PD
patients: 20 received bilateral post-commissural putaminal
grafts of ventral mesencephalic fetal neurons, and 20 had a
burr hole drilled into their skull as a sham procedure.
Immunosuppression was not administered. The fetal cells
were cultured for 1 week prior to transplantation. The
primary endpoint was patient self-reports on activities of
daily living (recorded at home for 12 months). The Olanow
et al. trial (2003) consisted of 34 PD patients: 11 received
bilateral post-commissural putaminal grafts of ventral
mesencephalic fetal neurons from one donor fetus, 12 from
four donor fetuses, and 11 received bilateral sham proce-
dures. Oral cyclosporine (CsA) immunosuppression was
administered to all patients starting 2 weeks prior to sur-
gery and continued for 6 months after grafting. The pri-
mary endpoint was the UPDRS motor subscore. Both trials
did not show significant differences between treatment
groups, although further analysis revealed that patients
younger than 60 years old or with less severe PD at base-
line had improvements in their parkinsonian signs. Positron
Emission Tomography (PET) imaging demonstrated
increased [18F]fluorodopa uptake in the grafted areas sug-
gesting graft survival that was later confirmed by post-
mortem examinations.
An unexpected outcome for both trials was the occur-
rence of what was then named ‘‘runaway’’ dyskinesias, also
known as graft-induced dyskinesias (GIDs). Unlike typical
PD dyskinesias that are induced by chronic long-term L-
DOPA administration [see (Bezard et al. 2001)], these
uncontrolled abnormal movements were not associated
with antiparkinsonian medication and did not ameliorate
with reduction or cessation of L-DOPA treatment. GIDs
were observed in a quarter of the grafted patients in the
Freed et al. and half the Olanow et al. trials.
Several issues may have contributed to the onset of GIDs.
As patients that received the fetal mesencephalic grafts
presented focal points of increased PET signal (Ma et al.
2002), it was proposed that the grafts produced ‘‘hot spot’’
regions in which DA was being excessively released. To
answer the question of whether there was an association
between GIDs and focal versus widespread distribution of
cell grafts in the striatum (Maries et al. 2006), 6-OHDA-
treated rats received either a focal striatal transplant of
200,000 cells, or the same number of cells across six different
striatal locations. The experiment showed that GIDs were
only present in the focal graft recipients. It also brought to
light that the number of functional cells within a focal site
might be of equal concern. Another proposed contributing
factor for GIDs was that the chronic L-DOPA treatment
preceding the transplantation may have ‘‘primed’’ the
patients to have dyskinesias. In 6-OHDA-intoxicated rats, L-
DOPA pre-treatment affected graft integration and func-
tionality, although GIDs were present with or without L-
DOPA pre-treatment (Steece-Collier et al. 2009). A study in
24 systemic MPTP-treated vervet monkeys (Chlorocebus
sabaeus) assessed whether priming the animals to develop L-
DOPA-induced dyskinesias (LIDs), and then injecting allo-
geneic fetal dopaminergic cells in a ‘‘spread’’ or ‘‘hotspot’’
pattern would affect the development of GIDs (Kordower
et al. 2016). The investigators did not detect GIDs in any of
the monkeys, regardless of cell distribution or condition.
Possible species differences could be at play as well as
methods of cell preparation. A critical limitation of this
report is that the animals’ MPTP-induced parkinsonism
spontaneously improved overtime. All the monkeys pre-
sented similar mild PD scores with no differences between
grafted and control subjects. Thus, the graft’s antiparkinso-
nian efficacy or graft potential to produce true functional
hotspots could not be evaluated.
Inflammation has also been proposed to promote the onset of
GIDs through aberrant synapse formation between grafted
neurons and host striatal medium spiny neurons [MSNs;
(Soderstrom et al. 2008)]. This theory was derived from the
observation of GIDs in patients who did not receive immuno-
suppression following fetal engraftment or those that had been
recently taken off an immunosuppressive regimen. Interest-
ingly, the evaluation of spine density maintenance in MSNs
through administration of slow-release pellets of the calcium
channel antagonist nimodipine has led to intriguing evidence
about the importance of preserving MSNs for reducing LIDs
and transiently reducing GIDs (Soderstrom et al. 2010). Patient
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and rodent studies have also highlighted that serotonergic and
noradrenergic neurotransmission either by host innervation or
by mixed-cell grafts may contribute to GIDs (Shin et al. 2012).
As the cause of GIDs is being unraveled, new strategies aiming
to prevent or decrease GIDs are being evaluated.
Another potential complication for CBTs was uncovered in
2008, when follow-up postmortem analysis of PD patients
treated a decade earlier with fetal grafts found LB-like
pathology in the grafted cells (Kordower et al. 2008; Li et al.
2008). Although it is unclear how much the aggregates
affected the functionality of the grafts, the implication that PD
could be transferred to the grafted cells reverberated
throughout the field (see ‘‘Parkinson’s disease: then and
now’’). A preliminary confirmation of a-syn being transferred
into grafted cells was obtained in rats injected with adeno-
associated viral vector serotype 6 encoding for human a-syn
into the striatum after fetal cell engraftment (Kordower et al.
2011).
New clinical trials utilizing fetal mesencephalic tissue
for DA cell replacement are currently ongoing in Canada,
Europe (Transeuro), South Korea and Mexico (listed in:
clinical trials.gov and isrctn.com). The investigators lead-
ing these trials aim to optimize the approach by taking
advantage of the knowledge gained from the clinical and
preclinical studies described above.
Additional clinical trials using CBTs for DA cell
replacement in PD
A number of alternative sources for dopaminergic neurons,
including mesencephalic fetal porcine cells, cadaveric
human retinal-pigmented epithelium (hRPE) and autolo-
gous sympathetic and carotid ganglia, have been investi-
gated to avoid the surgical complication of using
autologous adrenal medullary tissue and to overcome the
practical and ethical limitations of using human fetal cells
for large-scale clinical applications. NHP preclinical stud-
ies were only performed for hRPE. The DA-producing
cells were attached to gel microcarriers (Spheramine) and
placed into the striatum of parkinsonian monkeys. The
grafts improved motor function and postmortem analysis
showed cell survival and a mild inflammatory reaction
(Watts et al. 2003). Controlled clinical trials for hRPE as
well as all the sources listed above failed to show a sig-
nificant antiparkinsonian effect (Fitzpatrick et al. 2009).
Ex vivo gene therapy for PD
Ex vivo gene therapy originated as a method to engineer
cells for delivery of therapeutic molecules (Raymon et al.
1997). The cells are typically genetically modified using
viral vectors. The main advantage of this method compared
to direct intracerebral viral vector delivery (in vivo gene
therapy) is that the transfected cells can be monitored
before transplantation for the effects of viral infection and
the production of a foreign protein. Safety, genetically
engineered, ‘‘tricks’’ have been developed to curtail
unwanted side effects, such as regulatable promoters to
stop gene expression and kill-switches to terminate the
cells and completely stop product synthesis.
Ex vivo gene therapy strategies have been developed for
DA replacement and trophic factor delivery with variable
results. MPTP-intoxicated rhesus monkeys received autol-
ogous fibroblasts genetically engineered to produce tyr-
osine hydroxylase [the rate-limiting enzyme for DA
production; e.g., (Bankiewicz et al. 2000)] with minimal
antiparkinsonian effects. Glial cell line-derived neu-
rotrophic factor (GDNF) producing C2C12 cells were
encapsulated and transplanted into MPTP-treated baboons
(Kishima et al. 2004) inducing only temporary improve-
ments of their parkinsonian symptoms, probably due to the
low survival of encapsulated cells which led to a low and
variable protein production. New cell sources for ex vivo
gene therapy (see below) are emerging. For example,
human neuroprogenitor cells (hNPCs) have been shown to
survive and locally produce GDNF in the brain of
parkinsonian immunosuppressed rats and monkeys (Behr-
stock et al. 2006; Emborg et al. 2008). Although the clin-
ical translation for PD has not been pursued (probably due
to the poor results of GDNF protein delivery trials;
(Richardson et al. 2011)), a clinical trial for amyotrophic
lateral sclerosis is currently ongoing (http://www.clin
icaltrials.gov).
Stem cells as sources of cell lines
Biological research breakthroughs and development of new
technologies have paved the way for the identification of
stem cells (SCs) as new cell sources for regenerative
medicine approaches. SCs are defined by their self-renewal
capacity and their potential for becoming a different cell
type with a specialized function. These properties allow
researchers to create cell lines to be repurposed for in vitro
studies and transplantation.
hNPCs are typically obtained from the germinal layer of
a fetal brain. Although they are not pluripotent SCs (they
are already fated toward a brain cell phenotype), in vitro
hNPCs can be expanded and differentiated to a DA phe-
notype (Sanchez-Pernaute et al. 2001). In MPTP-treated
monkeys, hNPCs induced improvements of PD signs and
postmortem analysis has shown their survival and migra-
tion. Their cell progeny seemed to differentiate in vivo into
DA-like neurons and glial phenotypes and overall have a
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‘‘homeostatic’’ impact (Bjugstad et al. 2005, 2008; Red-
mond et al. 2007). It should be noted that NPCs have been
found in the adult human and NHP brains (Eriksson et al.
1998; Gould et al. 1999). These findings, plus earlier
studies in rodents, refuted the idea that the adult brain is
incapable of forming new neurons (Altman and Das 1965;
Buzanska et al. 2002; Kaplan and Hinds 1977; Kemper-
mann et al. 1997). The option of recruiting resident hNPCs
for brain repair has tantalizing possibilities but its utility
has not yet been proven (Rakic 2004). Interestingly, one
study grafted autologous adult cortical cells (cultured for a
couple of weeks) into the caudate of MPTP-intoxicated
vervet monkeys. Grafted cells were found 4 months post-
surgery and their presence was associated with increased
local levels of GDNF (Brunet et al. 2009).
Bone marrow, umbilical cord blood and adult adipose-
derived stromal tissue (Fallahi-Sichani et al. 2007; Levy
et al. 2008; McCoy et al. 2008) have been proposed as SC
sources as they can be obtained for autologous grafts.
Although NHP studies with these cells have not been
performed, evaluation in rodents suggests that they produce
trophic factors that could be beneficial for PD. Several
clinical trials are currently ongoing to test the safety and
efficacy after administration of mesenchymal stem cells
through intravenous, intracarotid or intranasal routes
(clinicaltrials.gov). Intravenous infusion of adipose-derived
stromal vascular fraction cells is also being investigated for
safety and efficacy, as well as for benefits to the quality of
daily living in PD patients.
Embryonic stem cells (ESCs) obtained from blastocysts are
pluripotent SCs, thus they have the potential to become any
cell of the body. In 1995, Thomson et al. (Thomson et al. 1995)
reported the isolation of ESCs from rhesus monkeys. Com-
mon marmoset ESCs were isolated in 1996 (Thomson et al.
1996), followed in 1998 by human ESCs [hESC; (Thomson
et al. 1998)]. Differentiation of ESCs into a DA phenotype was
first accomplished in mice (Lee et al. 2000), followed a few
years later in human (Perrier et al. 2004; Yan et al. 2005) and
rhesus (Takagi et al. 2005). Since then, investigators have
been looking for more efficient ways to produce mesen-
cephalic DA neurons, as well as to solve the problems of
intracerebral graft survival and other challenges identified by
the fetal tissue trials. The ethical dilemma of the cells’ origin
triggered the 2001 restriction of USA federal funding for
hESC research to studies performed on authorized cell lines,
limiting the chances for creating new ones. The 8-year ban on
federal funding for ESC research was lifted on March 9, 2009.
Parthenogenesis, somatic cell nuclear transfer and altered
somatic cell nuclear transfer have been proposed as alternative
sources of pluripotent SCs (Kastenberg and Odorico 2008). In
NHPs, parthenogenesis has been used to generate an SC line
from cynomolgus monkeys (cyno-1). Parthenogenesis is an
asexual form of reproduction; although mammalian eggs
cannot fully develop, they can provide blastocysts to generate
parthenogenesis-derived ESCs. Using the cyno-1 cell line,
investigators differentiated the cells into dopaminergic neu-
rons (Perrier et al. 2004). These cells were successfully
transplanted into 6-OHDA-treated rats and one MPTP-treated
cynomolgus monkey (Sanchez-Pernaute et al. 2008). hNPCs
generated from parthenogenetic hSCs (hpNPCs) have been
evaluated in rats and MPTP-lesioned vervet monkeys
immunosuppressed with a combination of cyclosporine,
prednisone and azathioprine (Gonzalez et al. 2015, 2016). The
investigators first demonstrated graft survival and increased
DA striatal levels 3 months post-surgery in two NHPs (Gon-
zalez et al. 2015). Antiparkinsonian efficacy of hpNPCs was
then evaluated in 18 monkeys (Gonzalez et al. 2016). The
animals were matched according to disability and assigned to
one of 3 treatment groups: vehicle (n = 6), low (n = 6) and
high (n = 6) cell dosing. Cells were inoculated in the caudate,
putamen and substantia nigra. Twelve months post-grafting,
the low dose animals showed significant behavioral
improvements compared to their baseline condition; however,
no significant differences between vehicle and dosing groups
were detected. A clinical trial to assess the safety and tolera-
bility of hpNPCs in PD is currently ongoing in Australia
(clinical trials.gov). Three patient groups (each to receive
different cell number doses) of four patients each who have
moderate to severe PD will receive between 30 and 70 million
cells injected into the striatum and substantia nigra.
The development of induced pluripotent stem cells
(iPSCs) from somatic cells (Takahashi et al. 2007a, b; Yu
et al. 2007) has further facilitated the production of addi-
tional cell lines for regenerative medicine and disease
modeling purposes. iPSCs represent a major advancement
towards personalized medicine as cells can be generated
from the prospective recipient. iPSCs have been generated
from macaque (Deleidi et al. 2011; Liu et al. 2008) and
marmoset (Tomioka et al. 2010; Wiedemann et al. 2012;
Wu et al. 2010; Vermilyea et al. 2016a) monkeys. The
derivation of iPSCs has been modified in recent years using
expression plasmids that do not integrate into the host
DNA, which increases their safety for clinical translation.
NHP studies assessing SC-derived DA cell
replacement strategies
Over the past decade, several NHP studies have analyzed the
potential use of SCs from different sources and at different
stages of differentiation for DA cell replacement (Table 2).
Takagi et al. investigated monkey ESC-derived neural
progenitors capable of producing dopaminergic neurons for
transplantation into an NHP model of PD (Takagi et al.
2005). ESCs from a cynomolgus monkey (Macaca fasci-
cularis) were differentiated on stromal cells with the
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addition of FGF2 and FGF20, and labeled in vitro with
BrdU for postmortem identification. The ESC-derived
dopaminergic progenitor cells were then transplanted into
systemic MPTP-treated cynomolgus monkeys. Beginning
at 10 weeks post-brain surgery, the neurological parkin-
sonian scores of animals receiving grafts (n = 6) decreased
significantly (p\ 0.05) compared with sham controls
(n = 4) and were associated with a significant increase in
striatal [18F]fluorodopa uptake observed by in vivo PET.
Postmortem analysis at 14 weeks post-grafting verified
survival of BrdU/TH colabeled neurons. Neither mitosis
(identified by Ki67-immunoreactivity) nor tumor formation
was observed in animals that received ESC-derived neu-
ronal transplants.
Aiming for human translation, Kriks et al. differentiated
floorplate-derived dopaminergic neurons from human
ESCs (hESCs), labeled half of the cells with GFP and then
transplanted the labeled cells into one side of the striatum,
and unlabeled cells to the other, of two systemic MPTP-
treated rhesus monkeys immunosuppressed by CsA
administration (Kriks et al. 2011). At one-month post-
transplantation, grafted cells were observed in the posterior
caudate and pre-commissural putamen as well as Iba1?-
cells, suggesting immunoreaction by the host. Daadi et al.
2012 and Wakeman et al. 2014 tested hESC-derived
DAergic neurons expressing GFP in the caudate and nigra
of MPTP-intoxicated vervet monkeys immunosuppressed
with cyclosporine, prednisone and azathioprine (Daadi
et al. 2012; Wakeman et al. 2014b). The 4 monkeys treated
by Daadi et al. showed a few TH-positive grafted cells,
extending neurite outgrowth and expressing synaptic
markers 2 months post-surgery; cell counts of grafts and
immunological response were not reported. In the Wake-
man et al. study, the two monkeys presented co-expression
of GFP and bIII-tubulin positive cells but not TH, dopa-
mine transporter (DAT) or other markers of midbrain
floorplate differentiation 6 weeks after grafting, suggesting
de-differentiation; evaluation of inflammatory markers was
not reported. Emborg et al. also studied hESC-derived
DAergic neurons; however, the brain evaluations were
performed 3 months after grafting. The cells were geneti-
cally engineered to express GFP and grafted in the striatum
and nigra of three rhesus monkeys that received MPTP by
carotid artery injection. The three animals were immuno-
suppressed by daily oral dosing of cyclosporine that was
started 48 h prior to grafting (Emborg et al. 2013b). Post-
mortem analysis at 3 months revealed graft survival in only
one of the three monkeys. The graft was infiltrated with
GFAP, CD68 and CD45 immunoreactive cells, suggesting
ongoing immune reaction despite immunosuppression.
These results further demonstrated that immunological
issues are a major concern for xenografts and that
allogeneic or autologous transplants may render better graft
survival and integration.
Grafts of human iPSC (hiPSC)-derived dopaminergic
neurons have also been attempted. In 2011, Kikuchi
et al. reported their evaluation of grafting into one
FK506 immunosuppressed MPTP-treated monkey
(Kikuchi et al. 2011). The hiPSCs were differentiated
into DAergic neural progenitors in feeder-free conditions
but were not labeled. Day 28 (d28) and d42 neuro-
spheres were transplanted into the right and left puta-
men, respectively. Graft size and function was evaluated
at 1, 3 and 6 months by MRI and at 6 months by PET




to assess for DA synthesis, vesicle transport, and DA
reuptake, and with 30-deoxy-303[18F]fluorothymidine
([18F]FLT) to visualize cell proliferation. Interestingly,
MRI showed increase in graft size on the side of grafted
d28 neurospheres compared to d42. In general, PET did
not identify any meaningful graft-related uptake, with
exception of increased binding of ([11C]PE2I) in the
d42-grafted putamen, suggesting cell differentiation.
Neurological evaluation throughout the study showed no
behavioral recovery. Postmortem analysis 6 months after
transplantation revealed graft survival; d42 spheres pro-
duced higher amounts of TH?cells compared with the
d28 spheres, while also maintaining some progenitor
populations, which explains the observed intracerebral
graft growth; immunological response was not reported.
A major advantage of iPSC technology is that patient-
specific cells can be generated for grafting, which mini-
mizes host immune reaction and avoids immunosuppres-
sion. In 2013, Emborg et al. reported their findings in three
rhesus monkeys that received an intracarotid artery injec-
tion of MPTP, followed 6 months later with autologous
iPSC-derived neuroprogenitors into the striatum and nigra,
without immunosuppression [Fig. 2; (Emborg et al.
2013a)]. For identification, the cells were genetically
modified to express GFP. Six months post-surgery, brain
analysis showed abundant GFP-positive neuron-like cells,
which integrated with the host brain and expressed TH.
Most importantly, infiltration of host immune cells
observed by CD3 and CD8 reactivity was minimal while
HLA-DR and GFAP were mild, similar to MPTP-induced
inflammation. Although neurological scores were not
reported, it was mentioned that the animals’ PD motor
signs did not improve; the lack of recovery was probably
due to low numbers of DAergic neurons grafted. Shortly
after, Morizane et al. compared autologous and allogeneic
transplantation of iPSC-derived neural cells in intact
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cynomolgus monkeys (Morizane et al. 2013). As expected,
the allogeneic transplants elicited a marked immune
response observed, with in vivo PET, as increased uptake
of [11C]PK11195 compared to the autografts, further
emphasizing the benefit of self-derived cells for transla-
tional applications.
In 2015, Hallett et al. reported that the differentiation
protocols used to generate iPSC-derived DAergic neurons
could be a factor for survival and functional integration of
grafted cells (Hallett et al. 2015). After ten cynomolgus
monkeys were rendered stably parkinsonian through sys-
temic MPTP administration, the animals received iPSC- or
ESC-derived DAergic grafts differentiated following three
different protocols: (Cooper et al. 2010) (n = 1), (Sund-
berg et al. 2013) (n = 2), and a modified (Sanchez-Per-
naute et al. 2005) (n = 3; for ESCs); no transplanted
animals (n = 4) were used as controls. The grafts derived
from the Sanchez–Pernaute differentiation protocol did not
survive and were thus separately analyzed as the non-sur-
viving transplant group, compared with the Cooper- and
Sundberg-derived grafts. Only the animal that received
cells using the Cooper differentiation protocol presented
functional recovery of daytime activity and movement
analysis. The animal recovered to pre-MPTP levels for
global activity, and improved in fine motor skills after
2 years. [11C]CFT PET imaging corroborated graft func-
tion with increased uptake around the transplant site. The
lack of functional recovery and survival of the Sundberg
and Sanchez-Pernaute grafts provide evidence that DAer-
gic differentiation patterning may be critical for functional
integration.
Wang et al. also assessed the feasibility of autologous
iPSC-derived DAergic neuron grafts to one MPTP-trea-
ted cynomolgus monkey (Wang et al. 2015). Throughout
the 6-month survival period, only between 6–8, and
22–24 weeks, the transplant monkey appeared to have an
improved clinical rating compared with the control
monkeys (n = 3). Postmortem analysis in the trans-
planted monkey showed graft survival and TH
immunoreactivity.
An examination of these SC-based studies highlights
that, similar to the fetal tissue reports in NHPs, they were
mainly feasibility/safety experiments, performed in a few
animals (with exception of Takagi et al. 2005) and focusing
on assessing cell survival, cell proliferation/tumor forma-
tion and whether the grafted cells integrated and showed a
DA phenotype. Some antiparkinsonian effects were
described. Considering the ongoing improvements on SC
research, this approach shows responsible use of the NHP
resource and also underscores that the results should be
kept in perspective with the limitations of the experimental
design and outcome measures utilized.
Nigral vs. striatal targets
For DA cell replacement, the field strives to recreate and
purify A9 DA nigral cells, yet in patients, the cells have
been mainly transplanted in the postcommisural putamen
[see review: (Redmond 2002)] with a few exceptions in
which the fetal nigral cells were placed in the nigra and
putamen [e.g.: (Mendez et al. 2002); Fig. 3]. Putaminal
targeting aims to provide DA in the area where needed,
while nigral grafting is proposed to restore the nigrostriatal
pathway, including the regulation of grafted cell activity
and restoring the DA tone in the substantia nigra pars
reticulata.
Theoretically, the nigral location is a most optimal
method for brain repair, yet an obstacle for its application
is the long distance to be covered by the axons of cells
inoculated in the nigra to reach their striatal targets. The
successful reconstruction of the nigrostriatal pathway
requires time for axonal extension, axonal guidance and
ultimately recognition and synaptic connection with tar-
gets. In rodents, the feasibility and advantages of the
approach have been reported using fetal cells (Mendez
et al. 1996) and ESCs (Grealish et al. 2014), observing
positive behavioral effects as soon as 6 weeks post-fetal
grafting and 18 weeks with ESC-derived DA cells, with the
latter requiring more time to mature and integrate in the
host. In NHPs and humans, the nigrostriatal distance is
greater, which means that the time needed after grafting to
observe behavioral benefits may also increase; therefore,
multisite grafting has been preferred.
The feasibility of grafting fetal midbrain cells in the
nigra (Collier et al. 2002) or in combination with fetal
striatal grafts for axonal guidance (Sladek et al. 2008) has
been demonstrated in MPTP-treated vervet monkeys; in
both studies axonal extension through the nigrostriatal
pathway and some modest caudal putamen reinnervation
was observed at 6 months; although follow-up studies of
co-grafting fetal nigra and striatum had limited effect
(Redmond et al. 2009). Localized delivery of trophic fac-
tors has been proposed as a method to stimulate and guide
axonal growth. Striatal GDNF overexpression via AAV2
vectors was reported to enhance the survival and outgrowth
of fetal dopamine neurons implanted in the striatum (Els-
worth et al. 2008). A follow-up comparison between
MPTP-intoxicated monkeys treated with AAV5 GDNF in
the caudate nucleus or solid fetal midbrain grafts in the
caudate and putamen or a combination of AAV-GDNF and
fetal grafts or buffered saline solution did not reveal greater
functional improvement in the AAV-GDNF and fetal grafts
monkeys during the 8 months of observation (Redmond
et al. 2013). AAV2-induced overexpression of GDNF in
the caudate supported outgrowth of fetal midbrain grafts
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maximally observed at 22 months post-grafting (Redmond
et al. 2009), as well as stimulated neurite extension and
dopaminergic differentiation of hNC grafts, both placed in
the nigra of MPTP monkeys (Wakeman et al. 2014a). The
studies suggest that reconstruction of the nigrostriatal
pathway can be achieved and that research on methods
aiming to promote and guide axonal growth is needed.
The future of CBTs and NHP studies
NHP studies have paved the way for the first clinical trials
using CBTs for PD. Although the number of monkey
experiments and/or total number of animals was a fraction
compared to rodent studies, they provided key evidence
that CBTs could be used to treat PD. NHP experiments
have facilitated the optimization of cell collection and
preparation methods, cell viability, as well as identify
potential brain targets. Today, old approaches are being re-
evaluated and optimized and new ones are being devel-
oped; some are being translated into the clinic (Barker
2014). NHP research can provide an even more crucial
insight into CBTs, but as a limited resource, prioritization
of issues to be evaluated will be critical. How cells are
prepared and stored affect engraftment, the methods of
delivery, the choice of targets and related timelines of
recovery are basic questions that still need to be solved and
tested in NHPs to improve CBT outcome. The response of
the host to the candidate CBT encompasses a different set
of topics related to efficacy, safety (e.g.: prevention of
GIDs), immunomodulation and inflammatory response and
propagation of a-syn. Each of these issues can also benefit
from careful NHP research.
Several groups are invested in the development of the
optimal cell for transplantation, working on generating cell
lines of ‘‘superdonors’’ with immunological compatibility
and improving the methods of cryoprotection to facilitate
clinical application, as creating a cell line per individual to
be treated would be a daunting task. While the idea of
testing in NHPs the same cell lines to be grafted to humans
is compelling, current data presented in this review high-
light the limitations of the xenograft approach with current
immunosuppression paradigms. Thus, a more parsimonious
approach would be to produce equivalent cells derived
from the same species, at least until the NHP equivalent of
severe combined immune deficiency (SCID) mice becomes
available (Sato et al. 2016).
Due to the brain volume and complexity of NHPs,
questions regarding intracerebral targets and graft distri-
bution will benefit from NHP studies and noninvasive
imaging approaches. For example, great strides have been
made towards the development and improvement of
intraoperative MRI (iMRI) methods (Mislow et al. 2009).
Silvestrini et al. (Silvestrini et al. 2015) used real-time
iMRI (RT-iMRI) for cell transplantation into a swine and
cadaveric human head as a concept for application in the
human brain. The platform technology utilizes a radially
branched deployment strategy to access multi-directional
deposit sites along a single cannula insertion tract. Our
group modified an RT-iMRI delivery system that has a
pivot point base, a clear silica cannula and inline pressure
monitoring system (Emborg et al. 2010, 2014) for the
in vivo delivery of DAergic progenitor cell spheres into the
putamen of a rhesus monkey [Fig. 4; (Vermilyea et al.
2016b)]. Malloy et al. (2016) used an MRI-compatible
delivery system for MRI monitoring of the distribution of
cells pre-labeled with a contrast agent into a baboon basal
ganglia. These new MRI-based imaging methods can
increase the safety and accuracy of the grafting procedures
and facilitate the evaluation of different targeting sites. In
that regard, imaging technologies, such as diffusion tensor
imaging (Hall et al. 2016), can be applied to preclinical
studies to evaluate circuit reconstruction, complementary
to traditional PET imaging with DA-related radioligands.
Application of imaging methods overtime to monitor graft
integration and function would be critical to reduce the
number of NHPs groups needed per experiment to under-
stand recovery timelines.
At this time, GIDs cannot be prevented or cured; NHP
safety studies on methods aiming to modulate grafted cell
activity are needed. Optogenetics is a technique that uses
light to control cells that have been genetically modified
to express light-sensitive ion channels (Lerner et al.
Fig. 2 An example of a grafted autologous rhesus IPSC-derived
dopaminergic neuron labeled with GFP (green) and immunostained
against TH (red); DAPI (blue). Scale bar 50 lm
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2016). Optogenetic approaches have been applied to
control electrophysiological and neurochemical properties
of grafted SC-derived DA neurons in rodent models
(Chen et al. 2015; Steinbeck et al. 2015), yet its clinical
translation is not recommended as the patients would
require the intracerebral placement of a probe to locally
deliver the appropriate light wavelength. Compared to
optogenetics, the designer receptors exclusively activated
by designer drugs (DREADDs) technology use noninva-
sive methods to exert its effects, as it depends on designer
drugs to modulate the activity of cells that are genetically
modified to express the corresponding receptor.
Fig. 3 Graphical depiction of a rhesus monkey brain hemisphere in
intact and PD-like conditions and with striatal and nigral grafts. The
main area of projection of nigral dopaminergic neurons is the
striatum, which is composed by the caudate nucleus and putamen. In
PD and PD-like conditions (e.g.: after MPTP intoxication), nigral
dopaminergic neurons die; thus, striatal dopamine (DA) is decreased.
Grafting of DA-producing cells into the striatum is envisioned as a
way to ensure DA availability in the area of projection. Nigral grafts
are proposed as a way to reconstruct the nigrostriatal pathway. Cd
caudate, ic internal capsule, Put Putamen, ac anterior commissure, cc
corpus callosum, Ctx cortex
Fig. 4 Real-time intraoperative MRI for intracerebral delivery of stem cells provides feedback of cannula placement and infusion site: a oblique,
b coronal, c sagittal and d horizontal planes
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DREADDs have been used to modulate human PSC-
derived DA neurons (Chen et al. 2016). There has been a
lot of discussion regarding CBT safety centered on
defining an adequate cell number and volume for intrac-
erebral delivery. The use of DREADDs or an equivalent
technology would allow more flexibility as, theoretically,
cells can be further excited if behavioral recovery is not
observed, or inhibited if serious GIDs occur. Basically, it
would provide a strategy for patient-specific graft modu-
lation that could be monitored by a combination of clin-
ical and PET imaging tools.
How can the value of the next generation of NHP studies
be maximized for the successful clinical translation of
CBTs for PD? We propose that first and foremost, the
investigators should use NHP PD models that match the
question at hand (Table 1). As we previously discussed,
until now all monkey studies of CBTs for PD have been
performed in neurotoxic models. Many basic questions
regarding feasibility, efficacy, and safety can be answered
in these models. Yet, the same way that only old animals
can provide insight on grafting in the aging brain, studies in
models of synucleinopathies are needed to assess the
impact of protein aggregation in graft efficacy. In that
regard, the field is anxiously waiting for the validation of
current genetic models and the availability of transgenic
and genomic edited PD monkeys. Second, a well-designed
feasibility study in a few monkeys presents an opportunity
to learn if an approach is worth pursuing, with the caution
that improvement of PD symptoms could be due to indi-
vidual variability or spontaneous recovery. Demonstration
of efficacy requires properly powered NHP experiments
with blind group assignment and evaluation. Third, the
surgical method of cell delivery is critical to ensuring
appropriate targets, optimized cell survival and distribution
and should not be minimized. Fourth, the animals should
be assessed with multiple outcome measures with clinical
impact to maximize the knowledge to be extracted from the
study. Behavioral evaluations complemented by in vivo
imaging methods can facilitate postsurgical follow-up,
especially for CBT studies taken several years to be com-
pleted. Postmortem analysis should include unbiased cell
counts and evaluation of host immunological response in
order to inform about the safety, efficacy and limitations of
the approach. Fifth, grafted cells should be pre-labeled to
facilitate identification from host cells. Images of grafts
should be in low and high magnification to assess the
extent of cell survival and interaction with host. Sixth,
there are no bad results, but poorly designed experiments.
Publication of positive as well as negative experimental
results in NHPs should be encouraged for the overall
evolution of the field.
To conclude, NHP PD research plays a small but critical
role in CBT clinical translation. Ultimately, investigators
should remember that whether CBTs for PD work will
depend on the benefits outweighing the patients’ risk and
that NHPs have unique characteristics to help identify and
solve these problems.
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